Welcome to LookChem.com Sign In|Join Free
  • or
(S)-1-(5-PHENYL-1H-IMIDAZOL-2-YL)ETHANAMINE is a chiral compound with a unique molecular structure, featuring an imidazole ring fused to a phenyl group and connected to an ethanamine moiety. This specific stereochemistry, with the (S)-configuration, is crucial for its biological activity and potential applications in the pharmaceutical industry.
Used in Pharmaceutical Industry:
(S)-1-(5-PHENYL-1H-IMIDAZOL-2-YL)ETHANAMINE is used as an intermediate in the synthesis of δ-opioid antagonists/μ-opioid agonists for potential therapy for diarrhea-predominant irritable bowel syndrome (IBS-d). Its unique structure and stereochemistry play a vital role in modulating the activity of opioid receptors, which can help in managing the symptoms of IBS-d by influencing the gastrointestinal motility and secretion.

864825-23-0

Post Buying Request

864825-23-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

864825-23-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 864825-23-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,4,8,2 and 5 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 864825-23:
(8*8)+(7*6)+(6*4)+(5*8)+(4*2)+(3*5)+(2*2)+(1*3)=200
200 % 10 = 0
So 864825-23-0 is a valid CAS Registry Number.
InChI:InChI=1S/C11H13N3/c1-8(12)11-13-7-10(14-11)9-5-3-2-4-6-9/h2-8H,12H2,1H3,(H,13,14)/t8-/m0/s1

864825-23-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 14, 2017

Revision Date: Aug 14, 2017

1.Identification

1.1 GHS Product identifier

Product name 1-(4-phenyl-1H-imidazol-2-yl)-ethylamine

1.2 Other means of identification

Product number -
Other names (alphaS)-alpha-Methyl-4-phenyl-1H-imidazole-2-methanamine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:864825-23-0 SDS

864825-23-0Relevant academic research and scientific papers

PROCESSES FOR THE PREPARATION OF ELUXADOLINE

-

Page/Page column 29-30; 31; 32, (2018/04/20)

The present invention relates to processes for the preparation of eluxadoline. The present invention also provides a compound of Formula V, a process for its preparation, and its use for the preparation of eluxadoline.

PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ELUXADOLINE

-

Page/Page column 9, (2017/05/28)

The invention relates to an improved process for preparing [(S)-1-(4-phenyl-1-H-imidazol-2- yl)-ethyl]-amine. The process involves formation of the novel intermediate crystalline compound[(S)-1-(4-phenyl-1-H-imidazol-2-yl)-ethyl]-carbamic acid tert-butyl ester oxalate.

Identification of a dual δ or antagonist/μ or agonist as a potential therapeutic for diarrhea-predominant Irritable Bowel Syndrome (IBS-d)

Breslin, Henry J.,Diamond, Craig J.,Kavash, Robert W.,Cai, Chaozhong,Dyatkin, Alexey B.,Miskowski, Tamara A.,Zhang, Sui-Po,Wade, Paul R.,Hornby, Pamela J.,He, Wei

, p. 4869 - 4872 (2012/08/13)

A small set of acyclic analogs 5 were prepared to explore their structure-activity relationships (SARs) relative to heterocyclic core, opioid receptor (OR) agonists 4. Compound 5l was found to have very favorable OR binding affinities at the δ and μ ORs (r Ki δ = 1.3 nM; r Ki μ = 0.9 nM; h Ki μ = 1.7 nM), with less affinity for the κ OR (gp Ki κ = 55 nM). The OR functional profile for 5l varied from the previously described dual δ/μ OR agonists 4, with 5l being a potent, mixed dual δ OR antagonist/μ OR agonist [δ IC50 = 89 nM (HVD); μ EC50 = 1 nM (GPI); κ EC50 = 1.6 μM (GPC)]. Compound 5l has progressed through a clinical Phase II Proof of Concept study on 800 patients suffering from diarrhea-predominant Irritable Bowel Syndrome (IBS-d). This Phase II study was recently completed successfully, with 5l demonstrating statistically significant efficacy over placebo.

PROCESS FOR THE PREPARATION OF OPIOID MODULATORS

-

Page/Page column 28-29, (2008/06/13)

The present invention is directed to novel processes for the preparation of opioid modulators (agonists and antagonists) and intermediates in their synthesis. The opioid modulators are useful for the treatment and prevention of as pain and gastrointestina

NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS

-

Page/Page column 32, (2010/02/13)

The present invention is directed to novel opioid receptor modulators of Formula (I). The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 864825-23-0